ClinicalTrials.gg
CompletedNCT00766675Updated Jul 3, 2013Results posted

An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain

A Phase 4 interventional study of Tramadol hydrochloride and Acetaminophen in Pain and Fibromyalgia, sponsored by Johnson & Johnson Taiwan Ltd. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-03.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies testing tramadol in Pain — 1 open to participants now, 1 under way, none of them phase 3. Tramadol · Pain.

Enrollment
25th of 37
80 · median 108
Started
2008
with 5 others
Phase 4
12 of 37
none open now
Registered
13th of 37
by date
Lead sponsor
3 of 37
Johnson & Johnson Taiwan Ltd

Among the 37 studies testing tramadol in Pain, this one is the 25th largest by enrollment, is one of 6 that started in 2008, is one of 12 in phase 4, and was the 13th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 37 studies testing tramadol in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing tramadol in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the analgesic effect of combination of tramadol hydrochloride and acetaminophen in participants for treatment of fibromyalgia pain (chronic widespread pain and presence of tender points).

Read the detailed description

This is an open-label (all people know the identity of the intervention) and multi-center (conducted in more than one center) study of combination of tramadol hydrochloride and acetaminophen in treatment of participants with pain of fibromyalgia. The duration of this study will be 56 days per participant. The study consists of 2 parts: Screening (that is, 3 weeks before study commences on Day 1) and Treatment (that is, up to Day 56). All the eligible participants will receive oral tablet for combination of tramadol hydrochloride and acetaminophen. Rescue medication (a medication intended to relieve symptoms immediately) of tylenol (500 milligram, up to 6 oral tablets daily) will be permitted throughout the study duration. Efficacy of the participants will primarily be evaluated by Pain Visual Analog Scale. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Pain
  • Fibromyalgia

Keywords

  • Pain
  • Fibromyalgia
  • Ultracet
  • Tramadol Hydrochloride
  • Acetaminophen
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the American College of Rheumatology 1990 criteria for the classification of fibromyalgia (that are, Participants must have had widespread pain [pain in three quadrants and in the axial skeleton] for at least three months and pain on digital palpation in 11 or more of the 18 tender-point sites
  • Female participants must not be pregnant, breast feeding or for at least one year
  • Participant must be able to take oral medication
  • Participants must have completed the Screening or wash-out procedures and have a visual analog scale score greater than or equal to 40 milliliter
  • Fail to non-opioid analgesics

Exclusion criteria

Exclusion Criteria:

  • Participants who previously failed tramadol hydrochloride therapy or those who discontinued tramadol hydrochloride due to adverse events
  • Participants diagnosed with either any active connective tissue or musculo-skeletal diseases, or or history of malignancy within past 5 years, or painful, symptomatic osteoarthritis, or regional periarticular pain syndromes, spondyloarthropathy and major endocrine disease
  • Participants who currently have more severe pain than the pain of fibromyalgia
  • Participants who have taken antidepressants, cyclobenzaprine or anti-epileptic drugs for pain within three weeks of the Treatment Phase
  • Participants who have taken short-acting analgesics, topical medications and anesthetics and/or muscle relaxants for a period of less than 21 days of the given medication prior to the Treatment Phase
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Tramadol hydrochloride/acetaminophen

    Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.

    Drug: Tramadol hydrochloride · Drug: Acetaminophen

Interventions

  • Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.

  • Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.

06

What researchers measure

Primary outcomes

  1. Pain Visual Analog Scale Score at Day 14

    Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

    Time frame: Day 14

  2. Pain Visual Analog Scale Score at Day 28

    Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

    Time frame: Day 28

  3. Pain Visual Analog Scale Score at Day 56

    Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

    Time frame: Day 56

Secondary outcomes

  1. Number of Participants With Categorical Scores on Pain Relief Rating Scale

    Pain Relief Rating Scale was used to measure the amount of pain relief experienced (on average) relative to the no-medication Screening or wash-out phase using a 6-point Likert scale ranging from (-) 1 to 4 and rated as (-) 1=worse, 0=None, 1=Slight, 2=moderate,3=a lot and 4=complete.

    Time frame: Day 14, 28 and 56

  2. Tender-Point Evaluation/ Myalgic Score

    Eighteen tender-point sites were evaluated by digital palpation for pain by the same Investigator at each site. The Investigator rated the participant's response to digital palpation on a scale from 0 (no pain \[participant did not have a tender point\]) to 3 (participant withdrawn or flinched). Total myalgic score was the sum of tender-point pain ratings.The total tender-Point score ranges from 0 to 18, and the total myalgic score ranges from 0 to 54. Higher score indicates worsening.

    Time frame: Baseline and Day 56

  3. Sleep Questionnaire: Number of Hours to Fall Asleep and Participant Slept

    The patient assessment sleep questionnaire consisted of 12-Questions (Q) to evaluate the participant's sleep habits out of which Q1 was "How long did it usually take for participant to fall asleep during the past 4 weeks" and Q2 was "On the average, how many hours did participant sleep each night during the past 4 weeks".

    Time frame: Baseline and Day 56

  4. Participant Assessment Sleep Questionnaire Score

    Sleep questionnaire consisted of 12-Questions (Q), Q3-Q12 were related to "How often during past 4 weeks did participant felt" and are as: Q3: sleep not quiet, Q4: get enough sleep to feel rested upon waking in morning, Q5: awaken short of breath or with headache, Q6: feel drowsy or sleepy, Q7: have trouble falling asleep, Q8: awaken during sleep time and have trouble falling asleep again, Q9: trouble staying awake during day, Q10: snore, Q11: take naps during day, Q12: get amount of sleep needed. Score ranged from 1= all the time to 6 = none of the time, higher score indicates improvement.

    Time frame: Baseline and Day 56

  5. Total Fibromyalgia Impact Questionnaire (FIQ) Score

    The FIQ was 19-item questionnaire which measured participant status, progress and outcomes. First 10 items made up of a physical functioning scale, ranging from 0 (always) to 3 (never). Items 11 and 12 asked participants to mark the number of days they felt well (0-7 days) and missed work (0-5 days). Items 13-19 were measured using 10 centimeter (cm) visual analog scale, score ranging from 0 cm (no) to 10 cm (very). Total FIQ score ranged from 0 -100 which was calculated as sum of final scores for item 1-10, 11 and 12, and individual score for item 13-19, and higher score indicates worsening.

    Time frame: Baseline and Day 56

  6. Number of Participants With Physician Global Assessment

    The treating physician rated the participant's condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participant's condition was indicated as very good, good, moderate, poor and very poor.

    Time frame: Day 14, 28 and 56

  7. Number of Participants With Subject's Global Assessment

    Participants indicated their condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participants indicated their condition as very good, good, moderate, poor and very poor.

    Time frame: Day 14, 28 and 56

07

Results

Posted Jul 3, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol Hydrochloride/Acetaminophen
Started80
Completed40
Not completed40
Withdrew: Adverse event16
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject11
Withdrew: Protocol violation8
Withdrew: Participant took prohibited medication1
Withdrew: Receive other anti-neoplastic treatment1
Withdrew: Insufficient therapy1

Outcome measures

PrimaryPain Visual Analog Scale Score at Day 14

Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

Time frame:
Day 14
Reported as:
Mean · Millimeter (mm)
Pain Visual Analog Scale Score at Day 14
Millimeter (mm)Tramadol Hydrochloride/Acetaminophen
Pain Visual Analog Scale Score at Day 1453.0 ± 20.12
PrimaryPain Visual Analog Scale Score at Day 28

Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

Time frame:
Day 28
Reported as:
Mean · Millimeter (mm)
Pain Visual Analog Scale Score at Day 28
Millimeter (mm)Tramadol Hydrochloride/Acetaminophen
Pain Visual Analog Scale Score at Day 2849.6 ± 20.95
PrimaryPain Visual Analog Scale Score at Day 56

Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

Time frame:
Day 56
Reported as:
Mean · Millimeter (mm)
Pain Visual Analog Scale Score at Day 56
Millimeter (mm)Tramadol Hydrochloride/Acetaminophen
Pain Visual Analog Scale Score at Day 5644.9 ± 20.95
SecondaryNumber of Participants With Categorical Scores on Pain Relief Rating Scale

Pain Relief Rating Scale was used to measure the amount of pain relief experienced (on average) relative to the no-medication Screening or wash-out phase using a 6-point Likert scale ranging from (-) 1 to 4 and rated as (-) 1=worse, 0=None, 1=Slight, 2=moderate,3=a lot and 4=complete.

Time frame:
Day 14, 28 and 56
Reported as:
Number · Participants
Number of Participants With Categorical Scores on Pain Relief Rating Scale
ParticipantsTramadol Hydrochloride/Acetaminophen
A lot:Day 1412
Moderate:Day 1419
Slight:Day 1424
None:Day 144
Worse:Day 142
Missing:Day 1419
A lot:Day 2817
Moderate:Day 2823
Slight:Day 2814
None:Day 285
Worse:Day 283
Missing:Day 2818
A lot:Day 5625
Moderate:Day 5613
Slight:Day 5618
None:Day 569
Worse:Day 563
Missing:Day 5612
SecondaryTender-Point Evaluation/ Myalgic Score

Eighteen tender-point sites were evaluated by digital palpation for pain by the same Investigator at each site. The Investigator rated the participant's response to digital palpation on a scale from 0 (no pain \[participant did not have a tender point\]) to 3 (participant withdrawn or flinched). Total myalgic score was the sum of tender-point pain ratings.The total tender-Point score ranges from 0 to 18, and the total myalgic score ranges from 0 to 54. Higher score indicates worsening.

Time frame:
Baseline and Day 56
Reported as:
Mean · Units on a scale
Tender-Point Evaluation/ Myalgic Score
Units on a scaleTramadol Hydrochloride/Acetaminophen
Tender-Point Evaluation (right side):Baseline7.9 ± 1.2
Myalgic Score (right side):Baseline13.6 ± 4.0
Tender-Point Evaluation (left side):Baseline7.8 ± 1.2
Myalgic Score (left side):Baseline13.1 ± 4.1
Tender-Point Evaluation (right side):Day 564.9 ± 2.5
Myalgic Score (right side):Day 567.0 ± 5.3
Tender-Point Evaluation (left side):Day 565.1 ± 2.4
Myalgic Score (left side):Day 567.2 ± 5.2
SecondarySleep Questionnaire: Number of Hours to Fall Asleep and Participant Slept

The patient assessment sleep questionnaire consisted of 12-Questions (Q) to evaluate the participant's sleep habits out of which Q1 was "How long did it usually take for participant to fall asleep during the past 4 weeks" and Q2 was "On the average, how many hours did participant sleep each night during the past 4 weeks".

Time frame:
Baseline and Day 56
Reported as:
Mean · Hours
Sleep Questionnaire: Number of Hours to Fall Asleep and Participant Slept
HoursTramadol Hydrochloride/Acetaminophen
Question 1: Baseline3.2 ± 1.3
Question 2: Baseline5.4 ± 1.5
Question 1: Day 562.2 ± 1.2
Question 2: Day 566.4 ± 1.3
SecondaryParticipant Assessment Sleep Questionnaire Score

Sleep questionnaire consisted of 12-Questions (Q), Q3-Q12 were related to "How often during past 4 weeks did participant felt" and are as: Q3: sleep not quiet, Q4: get enough sleep to feel rested upon waking in morning, Q5: awaken short of breath or with headache, Q6: feel drowsy or sleepy, Q7: have trouble falling asleep, Q8: awaken during sleep time and have trouble falling asleep again, Q9: trouble staying awake during day, Q10: snore, Q11: take naps during day, Q12: get amount of sleep needed. Score ranged from 1= all the time to 6 = none of the time, higher score indicates improvement.

Time frame:
Baseline and Day 56
Reported as:
Mean · Units on a scale
Participant Assessment Sleep Questionnaire Score
Units on a scaleTramadol Hydrochloride/Acetaminophen
Question 3: Baseline2.5 ± 1.3
Question 4: Baseline4.5 ± 1.3
Question 5: Baseline3.8 ± 1.6
Question 6: Baseline2.9 ± 1.5
Question 7: Baseline2.9 ± 1.6
Question 8: Baseline2.9 ± 1.5
Question 9: Baseline3.5 ± 1.6
Question 10: Baseline3.4 ± 1.5
Question 11: Baseline3.3 ± 1.7
Question 12: Baseline4.7 ± 1.3
Question 3: Day 563.8 ± 1.3
Question 4: Day 563.5 ± 1.4
Question 5: Day 564.9 ± 1.1
Question 6: Day 564.3 ± 1.3
Question 7: Day 564.2 ± 1.5
Question 8: Day 564.4 ± 1.3
Question 9: Day 564.4 ± 1.4
Question 10: Day 564.6 ± 1.1
Question 11: Day 564.2 ± 1.4
Question 12: Day 563.8 ± 1.6
SecondaryTotal Fibromyalgia Impact Questionnaire (FIQ) Score

The FIQ was 19-item questionnaire which measured participant status, progress and outcomes. First 10 items made up of a physical functioning scale, ranging from 0 (always) to 3 (never). Items 11 and 12 asked participants to mark the number of days they felt well (0-7 days) and missed work (0-5 days). Items 13-19 were measured using 10 centimeter (cm) visual analog scale, score ranging from 0 cm (no) to 10 cm (very). Total FIQ score ranged from 0 -100 which was calculated as sum of final scores for item 1-10, 11 and 12, and individual score for item 13-19, and higher score indicates worsening.

Time frame:
Baseline and Day 56
Reported as:
Mean · Units on a scale
Total Fibromyalgia Impact Questionnaire (FIQ) Score
Units on a scaleTramadol Hydrochloride/Acetaminophen
Baseline (n=73)6.1 ± 1.55
Day 56 (n=51)4.0 ± 1.94
SecondaryNumber of Participants With Physician Global Assessment

The treating physician rated the participant's condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participant's condition was indicated as very good, good, moderate, poor and very poor.

Time frame:
Day 14, 28 and 56
Reported as:
Number · Participants
Number of Participants With Physician Global Assessment
ParticipantsTramadol Hydrochloride/Acetaminophen
Q1: Very good (Day 14)2
Q1: Good (Day 14)18
Q1: Moderate (Day 14)30
Q1: Poor (Day 14)10
Q1: Very poor (Day 14)2
Q1: Missing (Day 14)18
Q2: Very good (Day 14)19
Q2: Good (Day 14)23
Q2: Moderate (Day 14)14
Q2: Poor (Day 14)4
Q2: Very poor (Day 14)2
Q2: Missing (Day 14)18
Q3: Very good (Day 14)3
Q3: Good (Day 14)14
Q3: Moderate (Day 14)34
Q3: Poor (Day 14)10
Q3: Very poor (Day 14)1
Q3: Missing (Day 14)18
Q1: Very good (Day 28)3
Q1: Good (Day 28)20
Q1: Moderate (Day 28)19
Q1: Poor (Day 28)7
Q1: Very poor (Day 28)0
Q1: Missing (Day 28)31
Q2: Very good (Day 28)14
Q2: Good (Day 28)22
Q2: Moderate (Day 28)11
Q2: Poor (Day 28)2
Q2: Very poor (Day 28)0
Q2: Missing (Day 28)31
Q3: Very good (Day 28)3
Q3: Good (Day 28)23
Q3: Moderate (Day 28)17
Q3: Poor (Day 28)6
Q3: Very poor (Day 28)0
Q3: Missing (Day 28)31
Q1: Very good (Day 56)5
Q1: Good (Day 56)20
Q1: Moderate (Day 56)18
Q1: Poor (Day 56)8
Q1: Very poor (Day 56)1
Q1: Missing (Day 56)28
Q2: Very good (Day 56)13
Q2: Good (Day 56)22
Q2: Moderate (Day 56)13
Q2: Poor (Day 56)2
Q2: Very poor (Day 56)2
Q2: Missing (Day 56)28
Q3: Very good (Day 56)4
Q3: Good (Day 56)26
Q3: Moderate (Day 56)15
Q3: Poor (Day 56)6
Q3: Very poor (Day 56)1
Q3: Missing (Day 56)28
SecondaryNumber of Participants With Subject's Global Assessment

Participants indicated their condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participants indicated their condition as very good, good, moderate, poor and very poor.

Time frame:
Day 14, 28 and 56
Reported as:
Number · Participants
Number of Participants With Subject's Global Assessment
ParticipantsTramadol Hydrochloride/Acetaminophen
Q1: Very good (Day 14)5
Q1: Good (Day 14)8
Q1: Moderate (Day 14)32
Q1: Poor (Day 14)15
Q1: Very poor (Day 14)2
Q1: Missing (Day 14)18
Q2: Very good (Day 14)16
Q2: Good (Day 14)21
Q2: Moderate (Day 14)19
Q2: Poor (Day 14)3
Q2: Very poor (Day 14)3
Q2: Missing (Day 14)18
Q3: Very good (Day 14)3
Q3: Good (Day 14)8
Q3: Moderate (Day 14)38
Q3: Poor (Day 14)13
Q3: Very poor (Day 14)0
Q3: Missing (Day 14)18
Q1: Very good (Day 28)3
Q1: Good (Day 28)15
Q1: Moderate (Day 28)21
Q1: Poor (Day 28)7
Q1: Very poor (Day 28)3
Q1: Missing (Day 28)31
Q2: Very good (Day 28)16
Q2: Good (Day 28)16
Q2: Moderate (Day 28)13
Q2: Poor (Day 28)4
Q2: Very poor (Day 28)0
Q2: Missing (Day 28)31
Q3: Very good (Day 28)3
Q3: Good (Day 28)17
Q3: Moderate (Day 28)21
Q3: Poor (Day 28)8
Q3: Very poor (Day 28)0
Q3: Missing (Day 28)31
Q1: Very good (Day 56)4
Q1: Good (Day 56)18
Q1: Moderate (Day 56)19
Q1: Poor (Day 56)10
Q1: Very poor (Day 56)1
Q1: Missing (Day 56)28
Q2: Very good (Day 56)14
Q2: Good (Day 56)21
Q2: Moderate (Day 56)9
Q2: Poor (Day 56)4
Q2: Very poor (Day 56)4
Q2: Missing (Day 56)28
Q3: Very good (Day 56)4
Q3: Good (Day 56)16
Q3: Moderate (Day 56)25
Q3: Poor (Day 56)7
Q3: Very poor (Day 56)0
Q3: Missing (Day 56)28

Adverse events

Collected over Baseline up to Day 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol Hydrochloride/Acetaminophen—2/80 (2.5%)49/80 (61.3%)
Most frequent serious events
Most frequent serious events
EventTramadol Hydrochloride/Acetaminophen
Forearm fractureInjury, poisoning and procedural complications1/80
Road traffic accidentInjury, poisoning and procedural complications1/80
Most frequent other events
Showing 10 of 38
Most frequent other events
EventTramadol Hydrochloride/Acetaminophen
DizzinessNervous system disorders14/80
Dry mouthGastrointestinal disorders12/80
NauseaGastrointestinal disorders9/80
VomitingGastrointestinal disorders5/80
SomnolencePsychiatric disorders5/80
ConstipationGastrointestinal disorders4/80
VertigoNervous system disorders4/80
PruritusSkin and subcutaneous tissue disorders4/80
AstheniaGeneral disorders3/80
Drug eruptionImmune system disorders3/80

Baseline characteristics

Age Continuous
Age Continuous(Years)Tramadol Hydrochloride/Acetaminophen
Mean50.4 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol Hydrochloride/Acetaminophen
Female74
Male6
Pain Visual Analog Scale at Baseline
Pain Visual Analog Scale at Baseline(Units on a scale)Tramadol Hydrochloride/Acetaminophen
Mean71.3 ± 18.22
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2008
First posted
Oct 6, 2008
Start
Oct 2008
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Results first posted
Jul 3, 2013
Last update
Jul 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00766675
Responsible party
Sponsor
First posted
Oct 6, 2008
Start date
Oct 2008
Primary completion
Mar 2009
Completion
Apr 2009
Results posted
Jul 3, 2013
Last update
Jul 3, 2013

Study contacts

Johnson & Johnson Taiwan Ltd Clinical Trial
study director · Johnson & Johnson Taiwan Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion